Clene (CLNN) AI Stock Analysis

• Market Cap: $61.69M
• Dividend Yield: N/A
• Average Volume (3M): 228.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: -49.17%
• EPS Growth: 23.37%
• Country: US
• Employees: 75
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 10,333,980
• 10 Day Avg. Volume: 59,411
• 30 Day Avg. Volume: 228,697
• PEG Ratio: 0.02
• Price to Book (P/B): -4.17
• Price to Sales (P/S): 107.97
• P/FCF Ratio: -1.73
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 352.11
• Enterprise Value/Gross Profit: 428.14
• Enterprise Value/Ebitda: -2.84
• 1Y Price Target: $30.40
• Price Target Upside: 409.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $6.00 ▲(0.50% Upside)

Clene's overall stock score is primarily impacted by its poor financial performance and valuation, reflecting significant financial instability and ongoing losses. However, the positive corporate events related to promising clinical data provide a potential upside, offering hope for future growth and market positioning. The technical analysis indicates bearish momentum, further weighing down the score.

Positive Factors

Promising Clinical Data

The promising biomarker results for CNM-Au8 in ALS patients suggest potential breakthroughs in treatment, enhancing Clene's market positioning and long-term growth prospects.

Strategic Financial Management

The equity distribution agreement provides Clene with a pathway to raise capital, supporting its financial strategy and enabling continued investment in R&D.

Innovative Platform Technology

Clene's proprietary platform using nanotechnology positions it well in the biotechnology sector, offering a competitive edge in developing advanced therapies for neurodegenerative diseases.

Negative Factors

Financial Instability

Negative equity and high leverage indicate financial distress, limiting Clene's ability to invest in growth and posing long-term sustainability risks.

Declining Revenue

Significant revenue decline reflects challenges in market penetration and product adoption, impacting Clene's ability to generate sustainable cash flow.

Cash Flow Challenges

Severe cash burn and negative operating cash flow highlight liquidity issues, potentially affecting Clene's capacity to fund ongoing operations and R&D.

Clene Business Overview & Revenue Model

Company Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Clene generates revenue primarily through the development and commercialization of its therapeutic products. The company focuses on advancing its lead compounds through clinical trials, which may eventually lead to regulatory approval and market entry. Revenue streams may arise from partnerships with larger pharmaceutical companies, including licensing agreements, milestone payments, and royalties on product sales once therapies are approved. Additionally, Clene may receive funding through grants, public offerings, and private investments to support its ongoing research and development efforts.

Clene Financial Statement Overview

Summary

Clene is facing considerable financial challenges with declining revenues, high net losses, and negative equity. The substantial operating losses and cash flow issues highlight the need for strategic restructuring or additional capital infusion. The biotechnology sector's inherent risk is amplified by Clene's financial instability.

Income Statement

Clene has experienced significant revenue fluctuations with a decline from $654,000 in 2023 to $342,000 in 2024, reflecting a -47.71% revenue growth rate. The gross profit margin is relatively strong at 79.53%, but the company has negative net profit and EBIT margins due to substantial losses, with a net loss of $39.4 million in 2024.

Balance Sheet

The company has a negative stockholders' equity of -$8.86 million, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt of $20.84 million suggests significant leverage. With equity being negative, the equity ratio is also negative, signaling potential insolvency risks.

Cash Flow

Operating cash flow remains deeply negative at -$21.33 million, with a slightly improved free cash flow position over the year. The free cash flow to net income ratio indicates severe cash burn issues, and financing cash flow has decreased, showing potential challenges in raising capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.00K	342.00K	654.00K	473.00K	723.00K	206.00K
Gross Profit	176.00K	272.00K	533.00K	447.00K	434.00K	141.00K
EBITDA	-26.50M	-33.69M	-43.24M	-25.60M	-8.34M	-16.96M
Net Income	-30.50M	-39.40M	-49.50M	-29.92M	-9.74M	-19.28M
Balance Sheet
Total Assets	22.31M	27.34M	52.34M	44.49M	63.06M	68.24M
Cash, Cash Equivalents and Short-Term Investments	7.92M	12.15M	35.00M	23.32M	50.29M	59.27M
Total Debt	21.31M	20.84M	32.16M	31.82M	24.04M	4.32M
Total Liabilities	34.67M	36.19M	38.95M	41.26M	50.47M	67.90M
Stockholders Equity	-12.36M	-8.86M	13.39M	3.24M	12.60M	341.00K
Cash Flow
Free Cash Flow	-18.61M	-21.34M	-30.50M	-44.19M	-35.96M	-19.32M
Operating Cash Flow	-18.60M	-21.33M	-30.17M	-39.01M	-34.62M	-18.93M
Investing Cash Flow	-12.97K	6.32M	-1.50M	-10.16M	-1.33M	-387.00K
Financing Cash Flow	11.96M	-1.53M	42.16M	17.25M	27.11M	69.53M

Clene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Negative. The current price of 5.97 is below the 20-day moving average (MA) of 6.26, below the 50-day MA of 7.94, and above the 200-day MA of 5.42, indicating a neutral trend. The MACD of -0.48 indicates Negative momentum. The RSI at 41.35 is Neutral, neither overbought nor oversold. The STOCH value of 56.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLNN.

Clene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
CAMP	58 Neutral	$321.66M	-2.53	-172.70%	―	―	5.51%
ANTX	52 Neutral	$36.17M	-1.17	-45.91%	―	―	44.59%
CLNN	49 Neutral	$61.69M	-1.76	―	―	-49.17%	23.37%
DYAI	46 Neutral	$35.04M	-4.09	-244.15%	―	-0.66%	-8.43%
AKTX	42 Neutral	$9.21M	―	-196.60%	―	―	―

Clene Corporate Events

Clene Updates on CNM-Au8® ALS Program

On December 3, 2025, Clene Inc. hosted a conference call and webcast to provide an update on its CNM-Au8® program for amyotrophic lateral sclerosis (ALS). This event reflects the company’s ongoing efforts to advance its therapeutic solutions in the treatment of ALS, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Clene Announces Positive Biomarker Results for CNM-Au8

On December 3, 2025, Clene Inc. announced statistically significant biomarker results for CNM-Au8 in ALS patients, supporting an accelerated approval pathway. The results showed reductions in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP), linked to improved survival, reinforcing CNM-Au8’s potential as a disease-modifying treatment. Clene plans to present these findings to the FDA in a Type C meeting in early 2026, aiming for a New Drug Application submission.

The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Clene Enters Equity Distribution Agreement with Canaccord

Clene Inc., a company in the biotechnology sector, has entered into an equity distribution agreement with Canaccord Genuity LLC to sell up to $25 million in common stock. As of October 17, 2025, Clene has filed a prospectus supplement to offer an additional $18.88 million in shares, following previous sales totaling approximately $6.12 million, potentially impacting its financial strategy and market presence.

The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.